|
December 28, 1999
DYNAMIC QSSP FUND INVESTS IN PALADIN LABS INC.
December 23, 1999
PALADIN LABS INC. TO ACQUIRE THE CANADIAN LICENSE TO A LINE OF DERMATOLOGY
PRODUCTS FROM BAKER NORTON PHARMACEUTICALS, INC.
December 22, 1999
PALADIN LABS INC. TO PURCHASE NEUROSCIENCE PHARMA (NPI) INC.
December 3, 1999
PALADIN LABS INC. TO DISTRIBUTE THE NEXT GENERATION MORNING AFTER PILL IN
CANADA
November 25, 1999
PALADIN LABS INC. TO PARTICIPATE IN DYNAMIC QSSP FUND
November 18, 1999
PALADIN
LABS INC. HIRES DR. KATIA BETITO AS ITS NEW EXECUTIVE DIRECTOR OF
SCIENTIFIC AFFAIRS
November 12,1999
PALADIN
LABS INC. RECEIVES CONDITIONAL LISTING STATUS FROM THE TORONTO STOCK
EXCHANGE
October 29, 1999
PALADIN
LABS INC. REPORTS 44% INCREASE IN NET INCOME FOR FIRST NINE MONTHS OF
1999
October 22, 1999
PALADIN
LABS INC. ISSUES OPTIONS TO THOMAS WIGGANS
October 13, 1999
PALADIN
LABS INC. COMPLETES EXCLUSIVE LICENSE AGREEMENT WITH ANTHRA
PHARMACEUTICALS INC. TO COMMERCIALIZE VALSTARTM IN CANADA
October 1, 1999
PALADIN
LABS INC. ANNOUNCES THE ACQUISITION OF NITROL® FROM RHONE
POULENC RORER CANADA INC.
September 30, 1999
SYNSORB
BIOTECH INC. ANNOUNCES CANADIAN MARKETING AND DISTRIBUTION AGREEMENT
FOR SYNSORB CD® WITH PALADIN LABS INC.
September 16, 1999
PALADIN
LABS SIGNS EXCLUSIVE CANADIAN MARKETING AND DISTRIBUTION AGREEMENT FOR
CERUMOLTM
August 26, 1999
PALADIN
TO RECEIVE $700,000 FROM EXERCISE OF WARRANTS BY INNOVATECH DU GRAND
MONTRÉAL.
August 26, 1999
PALADIN
HIRES MR. DAVID MACNAUGHTAN AS ITS VICE PRESIDENT OF BUSINESS
DEVELOPMENT
August 16, 1999
PALADIN
COMPLETES LICENSE AGREEMENT WITH CONNETICS TO DEVELOP AND
COMMERCIALIZE RELAXIN (CONXN®) IN CANADA.
August 13, 1999
PALADIN
COMPLETES $200,000 PRIVATE PLACEMENT WITH ITS NEW CHIEF FINANCIAL
OFFICER
August 12, 1999
PALADIN
ANNOUNCES THE COMPLETION OF THE PURCHASE OF RIDAURA
August 1999
PALADIN
ANNOUNCES FINANCIAL RESULTS FOR 2ND QUARTER OF 1999.
July 29, 1999
PALADIN LABS SIGNS EXCLUSIVE CANADIAN MARKETING AND DISTRIBUTION FOR PACIST WITH BIOCHEM PHARMA
July 15, 1999
PALADIN
HIRES MR. LENNIE RYER AS ITS CHIEF FINANCIAL OFFICER & COMPLETES
$200,000 PRIVATE PLACEMENT
July 7, 1999
CONNETICS
ENTERS LICENSE AGREEMENT WITH PALADIN LABS TO DEVELOP AND
COMMERCIALIZE RELAXIN (CONXN®) IN CANADA
July 5th, 1999
PALADIN
LABS RECEIVES TPD APPROVAL FOR SALE OF PMS-TRYPTOPHAN 500 MG
June 30, 1999
PALADIN
ISSUES OPTIONS UNDER ITS STOCK OPTION PLAN
June 30th, 1999
PALADIN REPORTS RESULTS
FROM A PROOF-OF-CONCEPT STUDY FOR USE OF NEURALGON IN THE TREATMENT OF
TRIGEMINAL NEURALGIA
June 15, 1999
PALADIN
ACQUIRES THE DISTRIBUTION RIGHTS FOR ANTIZOL® (FOMEPIZOLE INJECTION)
FROM ORPHAN MEDICAL, INC.
June 11, 1999
PALADIN
ACQUIRES THE CANADIAN DISTRIBUTION RIGHTS FOR VALSTARTM FROM ANTHRA
PHARMACEUTICALS, INC.
June 3, 1999
PALADIN
SUBMITS 5% AMLEXANOX PASTE FOR CANADIAN REGULATORY APPROVAL
May 26, 1999
PALADIN
ANNOUNCES PURCHASE OF RIDAURA FROM PHARMASCIENCE INC. FOR $1,506,784.
May 26, 1999
PALADIN
ANNOUNCES RESULTS FOR FISCAL YEAR 1998 AND 1ST QUARTER OF 1999.
March 20, 1999
PALADIN ACQUIRES THE EXCLUSIVE CANADIAN LICENSE FOR SIALOR® FROM SOLVAY
February 15, 1999
PALADIN
RECEIVES CANADIAN DISTRIBUTION RIGHTS TO SUPLASYN FROM BIONICHE INC.
February 15, 1999
PALADIN
RECEIVES CANADIAN DISTRIBUTION RIGHTS TO CYSTISTAT FROM BIONICHE INC.
Send comments,
corrections, and suggestions to info@paladin-labs.com
© 2006 Paladin Labs, Inc., All Rights Reserved. Legal
Terms and Notices (The Fine Print)
|
